Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatment of hypothyroidism

Next Previous
X
Search
Trial Profile

A Phase 1 study of levothyroxine (XP-8121) to evaluate the pharmacokinetics, safety and tolerability, and potential for weekly dosing of the investigational, novel, subcutaneous (SC) injection for the treatment of hypothyroidism

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Levothyroxine sodium (Primary) ; Levothyroxine sodium
  • Indications Hypothyroidism
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Xeris Biopharma Holdings; XERIS Pharmaceuticals

    • Most Recent Events

    • 24 Mar 2023 Results (n=60) assessing the pharmacokinetics, dose proportionality, safety and tolerability of XP-8121 given subcutaneously (SC) and the relative bioavailability of SC XP-8121 oral (PO) levothyroxine (Synthroid), presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics.
    • 20 Oct 2022 According to a Xeris Pharmaceuticals media release, Xeris will host a conference call and webcast today, Thursday, October 20, 2022, at 8:30 a.m. Eastern Time. To pre-register for the conference call please use this link: https://www.netroadshow.com/events/login?show=f4a7da25&confId=43411 to discuss this trial results.
    • 20 Oct 2022 Results published in the Xeris Biopharma Media Release
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top